ESMO 2022 | DeFi trial: nirogacestat vs placebo for patients with progressing desmoid tumors

Robin Jones, MBBS, MRCP, MD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the randomised Phase III DeFi trial (NCT03785964) investigating nirogacestat compared to placebo for patients with progressing desmoid tumors. The primary endpoint of the trial was progression free survival (PFS). The trial was positive and the safety profile was good, however Prof. Jones highlights the risks of ovarian suppression. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.